Association of Sarcopenia With Rocuronium Use in Liver Transplant Recipients

Status: Recruiting
Location: See location...
Intervention Type: Device, Diagnostic test, Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Patients will be informed by obtaining consent when they meet the inclusion criteria. Written consent will be obtained when the patient arrives in the operating room. The patient's characteristics (gender, age, liver disease) and the biochemistry, hemogram and coagulation values taken before the surgery will be written on the prepared follow-up form. After the hand grip strength is recorded in kg with a mechanical thenar muscle dynamometer, the SARC-F test questionnaire consisting of five questions will be administered to the patient and the SARC-F score will be calculated and recorded. Routine monitoring (ECG, pulse oximetry, non-invasive blood pressure cuff, TOF monitoring, BIS monitoring) will be performed for the liver transplant recipient. The routine anesthesia induction protocol will be applied to the patient for liver transplant recipients (thiopental (5-7 mg/kg), fentanyl (1-2 mcg/kg) and rocuronium (0.6 mg /kg)), the time after rocuronium will be recorded and the reset time of the TOF device will be determined. After intubation, the intubation score will be recorded on the follow-up form as a value between 5 and 20. During the case, the times when the TOF value exceeds 30% and the times when diaphragm activity is detected at -3 cmH2O on mechanical ventilation will be recorded, 0.1 mg/kg rocuronium will be added as required for routine anesthesia follow-up. The phase of the transplant operation (Dissection-Anhepatic-Neohepatic) in which the added rocuronium is added will be specified. The transfusion content and amounts within the case will be recorded on the follow-up form. The extubation times in hours, the transfer time to the ward, the discharge time from the hospital and the need for reintubation of patients who are routinely transferred to the intensive care unit in an intubated state at the end of the case will be recorded.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Patients with American Society of Anesthesiologists (ASA) 2-3,

• Patients over the age of 18,

• Liver transplant recipient candidates who have agreed to receive an organ transplant

Locations
Other Locations
Turkey
Turgut Ozal Medicine Center Liver Transplantation Institute
RECRUITING
Malatya
Contact Information
Primary
Emre Arıkan, assistant doctor
arikanemre00@gmail.com
+905535822001
Time Frame
Start Date: 2025-04-01
Estimated Completion Date: 2026-01-01
Participants
Target number of participants: 3
Treatments
Active_comparator: liver transplantation recipients with sarcopenia
this arm includes patient with sarcopenia in liver transplantation recipient group.They determined with SARC-F score , hangrip dynamometer value in kilogram and psoas muscle area measurement based on lomber CT scan .
Placebo_comparator: liver transplantation recipients without sarcopenia
the patients are this arm whom all going liver tranplantation for any reason but they have no sarcopenia in diagnosis algorithm
Sponsors
Leads: Inonu University

This content was sourced from clinicaltrials.gov